- Motley Fool•6 hours ago
Seattle Genetics got a boost from Donald Trump's underdog victory last month.
- Business Wire•4 days agoSeattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted the first reported data from an ongoing phase 1/2 clinical trial evaluating ADCETRIS in combination with Opdivo in relapsed or refractory classical Hodgkin lymphoma at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016.
- Business Wire•4 days agoSeattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting
Seattle Genetics, Inc. , a global biotechnology company, today highlighted long-term follow-up data evaluating ADCETRIS in T-cell lymphoma at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016.
SGEN : Summary for Seattle Genetics, Inc. - Yahoo Finance
Seattle Genetics, Inc. (SGEN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||63.91 x 100|
|Ask||67.86 x 100|
|Day's Range||64.81 - 68.68|
|52 Week Range||26.02 - 75.36|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-82.85|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|